Evaluating PSMA-PET/CT for Prostate Cancer Recurrence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess progression-free survival in patients experiencing biochemical relapse after radical prostatectomy, utilizing a PSMA-PET/CT guided treatment approach. Participants will undergo centralized 68Ga-PSMA PET/CT imaging to determine the appropriate salvage treatment based on the findings. The study includes patients with prostate adenocarcinoma who have a specific PSA level at recurrence, and treatment options will vary depending on the imaging results. The approach includes various radiation therapy options and systemic therapies tailored to the patient's condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent
* Age \>18
* Patient suitable for 68Ga-PSMA PET/CT re-staging according to clinical practice (Previous radical prostatectomy with histological result of Prostate adenocarcinoma +/- postoperative prostate bed radiotherapy (adjuvant or salvage setting), with a biochemical relapse defined as a PSA \> 0.2 and \<1

Exclusion Criteria:

* ADT administration within 6 months from study enrollment
* Persistent elevation of PSA after RP measured within 16 weeks from surgery (\> 0.1 ng/ml)

Where it's running

• AOU Careggi Radiation Oncology Unit
  Florence, Italy Recruiting

Study contacts

• Principal investigator: Lorenzo Livi, Prof. — Azienda Ospedaliero-Universitaria Careggi
• Study coordinator: Lorenzo Livi, Prof.
• Email: lorenzo.livi@unifi.it
• Phone: +390557947264

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy

  This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT06957691

• How social, structural, and lifestyle factors relate to prostate cancer outcomes in diverse men

  This study looks at whether social and lifestyle factors help explain differences in prostate cancer outcomes among Black, Hispanic, and Asian men who have had a radical prostatectomy.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07690579

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Lower-dose radiation to parts of the prostate for some men with prostate cancer

  This study tests whether a smaller amount of radiation aimed at specific parts of the prostate can reduce side effects compared with giving the full prostate the same dose.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07635238

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

• Mini-tumors to guide treatment for aggressive prostate cancer

  We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.

  Recruiting Maastricht Radiation Oncology · Heerlen, Limburg and 2 other locations · NCT07004582

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.